

DMDG past Open and Joint meeting programmes

Open Meeting 2017

20 - 22 September 2017 - Robinson College, Cambridge, UK

Wednesday 20th September

- 11.00 **Delegates Arrive, Registration, put up posters** (Crusaz Wordsworth Building (CWB) – Foyer and Plenary Room)
- 12.00-13.00 **Lunch, Posters, Trade Exhibition** (CWB – Foyer and Plenary Room)
- 13.15-13.30 **Chair's Opening Address** (Auditorium)
Graeme Scarfe, AstraZeneca
- 13.30-14.40 **DMDG Fellow Lecture. Steve Hood** (Auditorium)
- 14.40-15.20 **Free communication session** (Auditorium)
Chair. Teresa Heslop, GSK
Speakers.
CYP Induction and the strategy that AstraZeneca has put in place to assess this with illustration using recent compound examples
Helen Rollison, AstraZeneca
Optimisation of CYP3A4 metabolism and inhibition; a deuteration approach
Lynsey Fazal, Astex
- 15.20-16.15 **Coffee, Posters, Trade Exhibition [inc. room key collection and check-in]** (CWB – Foyer and Plenary Room)
- 16.15-17.30 **Parallel Sessions**
P1a - Antibody Drug Conjugates – beyond small and large molecule ADME precepts (CWB - Syndicate Room)
Chair. Simon Chivers, ADC
Speakers.
Investigating the many facets of ADC metabolism using Mass Spectrometry
Conor Barry, MedImmune
LCMS analysis of therapeutic proteins requiring high sensitivity determination
Fabrizia Fusetti, QPS
- P1b - Drug Metabolism studies with Natural Products** (Auditorium)
Chair. Harriet Oldham
Drug Metabolism studies with Natural Products - a Journey
Harriet Oldham, Neem Biotech
The complexities of developing a natural product – From CMC to the Clinic (with a focus on PK)
Peter Kilford, Covance
Hyperforin (St. John's Wort) induced drug–drug interactions. Clinical overview & *in vitro* correlation
Niladri Chattopadhyay, Bayer
- 17.30-18.30 **Student Presentations - Poster Blitz** (Auditorium)
Chairs. Sherri Dudal, UCB and Olivia Corcoran, University of East London
- 19.00-20.30 **Dinner** (Dining Hall)
- 20.00-22.00 **Poster Session, Trade Exhibition, Drinks Reception** (CWB – Foyer and Plenary Room)
Hosts. Sherri Dudal, UCB and Olivia Corcoran, University of East London

Thursday 21st September

- 08.30-10.15 **New frontiers in 3D micro tissue-based screening technologies** (Auditorium)
Chair. Reiner Class, UCB BioPharma SPRL
Speakers.
Microcavity arrays as a novel DMPK-tool
Eric Gottwald, Karlsruhe Institute of Technology (KIT)
Adding metabolic competence to 3D cell-based assays using a microtissue-based microphysiological system
Kasper Renggli, ETH Zürich, Switzerland

- Understanding 3D liver organoids and their potential in ADME-Tox**
Clive Dilworth, Cyprotex (Evotec)
- HepatoPearl, a novel 3D liver spheroid model for drug-drug interaction screening**
Noushin Dianat, ESPCI, PSL University, Paris
- 10.15-10.50 **Coffee, Posters, Trade Exhibition (CWB – Foyer and Plenary Room)**
- 11.00-12.30 **Parallel Sessions**
- P2a – Translational PK/PD strategies in discovery and development of biologics (Auditorium)**
Chair. Igor Vostiar, Novartis Pharma AG
 Speakers.
Challenges in the early development of NBEs
Peter Lloyd, KinDyn Consulting Ltd
From Animal to Human with a new monoclonal antibody. An example of the use of pharmacokinetics only to assist on the choice of first in human dose
Olivier Petricoul, Novartis Pharma
Predicting ADC toxin delivery to tumor versus different organs and implications for toxin potency
Matthias Machacek, X LYO-X
Translational (PB)PK-PD of immuno-oncological antibody drugs and its role in early clinical strategy setting
Jeroen Elassaiss-Schaap, Gedmore B.V.
P2b – Tissue targeted therapeutics. DMPK strategies and considerations (CWB - Syndicate Room)
Chair. Wouter Driessen, F Hoffmann-la Roche Ltd.
 Speakers.
Improved delivery of paclitaxel to prostate tumours. a Membrane-Type Matrix Metalloproteinase (MT-MMP) targeted approach
Paul Loadman, University of Bradford
Use of prodrugs to target liver but minimise intestinal exposure of orally administered compounds
Stephan Fowler, Roche
Disposition of AZD4076 a GalNAc-conjugated anti-miR for the treatment of NASH
Madelaine Antonsson, AstraZeneca
The Counter-Intuitive Nature of Liver Uptake. Mechanistic Insights
Iain Martin, Merck
- 12.30-13.30 **Lunch, Posters, Trade Exhibition (CWB – Foyer and Plenary Room)**
- 13.00-13.30 **DMDG ABM (CWB – Syndicate Room)**
- 13.45-14.45 **Free communication session (Auditorium)**
Chair. Teresa Heslop, GSK
 Speakers.
Improving Scientific Outcome by Modifying the Bile Duct Cannulated Rat Model Utilised in ADME Studies
Lee Crossman, Covance
Strategies to Profile Aldehyde Oxidase Mediated Metabolism
Lloyd King, UCB
Strategies for biotransformation studies in oligonucleotide drug development
Lars Weidolf, AstraZeneca
- 14.45-15.45 **Genetically modified and humanized mice for DMPK (Auditorium)**
Chair. Ian Wilson, Imperial College
 Speakers.
Genetically Modified Mice and Their Application in DMPK and Safety Testing. Current Practice and Future Prospects
Roland Wolf, University of Dundee
- 15.45-16.15 **Coffee, Posters, Trade Exhibition (CWB – Foyer and Plenary Room)**
- 16.15-17.45 **Genetically modified and humanized mice for DMPK (Auditorium)**
Chair. Ian Wilson, Imperial College
An Investigation of the Metabolism and Pharmacokinetics of Lumiracoxib and Diclofenac in Normal, Chimeric Humanized and Murinized FRG Mice
Tony Dickie, Evotech

Translational PK/PD studies using a humanized mouse model of malaria

Maria Jose Lafuente-Monasterio, GSK

The Utility of the Humanized Mouse Model in Assessing Clinical Induction. Case study with Rifampin-Mediated Induction of Tamoxifen Metabolism

Jae Chang, Genetech

Panel discussion on modified mice

Ian Wilson, Imperial College - and discussion panel

19.30-01.00 **Drinks Reception, Conference Dinner and Entertainment (Bar, Dining Hall)**

Friday 22nd September

<09.00 **Room check-out**

09.00-10.30 **Diverse applications of translational science (Auditorium)**

Chair. Howard Burt, Simcyp

Speakers.

Human dose prediction in Discovery. strategy and case studies with small molecules

Simon Taylor, GSK

The Estrogen Receptor (ER) as a drug target. what are the PKPD learnings from fulvestrant, a selective ER degrader (SERD)?

Camila de Almeida, AstraZeneca

PBPK modelling - an industry perspective

Aarti Patel, GSK

Use of PBPK modeling for DDI evaluation – case examples of interactions with Health Authorities

Kenichi Umehara, Novartis

10.30-11.00 **Coffee (Dining Hall)**

11.00-12.30 **MSI for in-depth and in-focus Drug D4 (Discovery, Delivery, Distribution and Development) applications (Auditorium)**

Chair. Rob Vreeken, Janssen R&D

Accelerating molecular imaging. resolution, resolution and resolution

Ron Heeren, M4I, Maastricht University

Strategies and constrains in performing quantitative mass spectrometry imaging of endogenous and exogenous compound

Richard Goodwin, AstraZeneca, UK

Optimising spatial resolution using SIMS

Andy West, GSK, UK

Imaging the unimaginable with high-dimensional imaging

Vincent van Unen, LUMC, Leiden, NL

Overview of future trends

Rob Vreeken, Janssen R&D

12.30-12.45 **In-coming Chair's closing remarks (Auditorium)**

Rowan Stringer, Novartis

12.45-14.00 **Lunch and depart (Dining Hall)**